Kelly WK - Search Results

1

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S; From The Alliance for Clinical Trials in Oncology Genitourinary Committee. Ryan CJ, et al. Among authors: kelly wk. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):66-73. doi: 10.1038/s41391-019-0152-3. Epub 2019 May 3. Prostate Cancer Prostatic Dis. 2020. PMID: 31053766 Free PMC article.

2

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin.

Schultz PK, Kelly WK, Begg C, Liebertz C, Cohen L, Scher HI. Schultz PK, et al. Among authors: kelly wk. Urology. 1994 Aug;44(2):237-42. doi: 10.1016/s0090-4295(94)80138-x. Urology. 1994. PMID: 7519382 Free article. Clinical Trial.

3

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

Scher HI, Kelly WK. Scher HI, et al. Among authors: kelly wk. J Clin Oncol. 1993 Aug;11(8):1566-72. doi: 10.1200/JCO.1993.11.8.1566. J Clin Oncol. 1993. PMID: 7687666

4

Prostate cancer: how can a common disease be so controversial?

Kelly WK, Scher HI. Kelly WK, et al. Curr Opin Oncol. 1994 May;6(3):318-31. Curr Opin Oncol. 1994. PMID: 8080862 Review.

5

Acid phosphatase: defining a role in androgen-independent prostate cancer.

Steineck G, Kelly WK, Mazumdar M, Vlamis V, Schwartz M, Scher HI. Steineck G, et al. Among authors: kelly wk. Urology. 1996 May;47(5):719-26. doi: 10.1016/s0090-4295(96)00017-9. Urology. 1996. PMID: 8650872

6

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.

Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, Herr H, Scher HI, Icasiano E, Higgins G. Bajorin DF, et al. Among authors: kelly wk. Cancer. 2000 Apr 1;88(7):1671-8. Cancer. 2000. PMID: 10738226 Clinical Trial.

7

Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.

Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM. Small EJ, et al. Among authors: kelly wk. J Clin Oncol. 2000 Nov 1;18(21):3595-603. doi: 10.1200/JCO.2000.18.21.3595. J Clin Oncol. 2000. PMID: 11054432 Clinical Trial.

8

Chemotherapy for androgen- independent prostate cancer: myth or reality.

Kelly WK, Slovin SF. Kelly WK, et al. Curr Oncol Rep. 2000 Sep;2(5):394-401. doi: 10.1007/s11912-000-0058-0. Curr Oncol Rep. 2000. PMID: 11122870 Review.

9

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H. Kelly WK, et al. J Clin Oncol. 2001 Jan 1;19(1):44-53. doi: 10.1200/JCO.2001.19.1.44. J Clin Oncol. 2001. PMID: 11134194 Clinical Trial.

10

The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma.

Sherman EJ, Pfister DG, Ruchlin HS, Rubin DM, Radzyner MH, Kelleher GH, Slovin SF, Kelly WK, Scher HI. Sherman EJ, et al. Among authors: kelly wk. Cancer. 2001 Feb 15;91(4):841-53. Cancer. 2001. PMID: 11241254 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

226 results

Search Page